Grant: CIHR Fellowship
Direct Payment
$125,000.00
Membrane-tethered peptides: A novel paradigm to explore G protein-coupled receptor (GPCR) function.
FY 2008-09
Summary
GPCRs occupy a central role in human physiology and comprises for ~30% of current drug targets. To enable development of effective therapeutics, the molecular mechanisms underlying ligand-induced receptor activation as well as the range of potential tissue-specific functions modulated by individual GPCRs need to be better defined. To address these objectives, we have recently established a new approach, in which peptide ligands are tethered to the cell membrane as probes to explore GPCR function. We have shown that tethered peptides can selectively stimulate or block class B1 GPCRs, a group of ~15 clinically important receptors which are activated by intermediate size peptide hormones. The tethered peptide cDNA constructs are designed to encode a single protein which includes: (1) a transmembrane domain (TMD),(2) a flexible peptide linker extending from the TMD into the extracellular (EC) space, and (3) a class B1 hormone at the free amino(N)-terminal EC end. The recombinant nature of these constructs enables site-directed mutagenesis and generation of virtually unlimited numbers of tethered ligand variants, a feature that can be exploited to rapidly optimize activity as well as interconvert clinically important peptide agonists and antagonists. In this application, we propose to extend the tethered ligand strategy to class A receptors, the largest group of GPCRs (~360 members) which includes the majority of established as well as candidate therapeutic targets. Extension of our technology to class A GPCRs will set the stage to (a) better understand peptide-receptor interactions, (b) expedite the development of peptide therapeutics and (c) produce transgenic animals expressing tissue-specific tethered modulators to dissect the functions of selected GPCRs in vivo. It can be anticipated that the application of membrane-tethered ligands will significantly expand current insight into the biological roles of members of the GPCR superfamily.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
181373
Name
Fortin Jean-Philippe
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Membrane-tethered peptides: A novel paradigm to explore G protein-coupled receptor (GPCR) function.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$125,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Agonists; Antagonists; Cell-Based Assays; Confocal Microscopy; G Protein-Coupled Receptors; Molecular Biology; Molecular Pharmacology; Peptide Hormones; Radioligand Binding; Signal Transduction
Abstract
GPCRs occupy a central role in human physiology and comprises for ~30% of current drug targets. To enable development of effective therapeutics, the molecular mechanisms underlying ligand-induced receptor activation as well as the range of potential tissue-specific functions modulated by individual GPCRs need to be better defined. To address these objectives, we have recently established a new approach, in which peptide ligands are tethered to the cell membrane as probes to explore GPCR function. We have shown that tethered peptides can selectively stimulate or block class B1 GPCRs, a group of ~15 clinically important receptors which are activated by intermediate size peptide hormones. The tethered peptide cDNA constructs are designed to encode a single protein which includes: (1) a transmembrane domain (TMD),(2) a flexible peptide linker extending from the TMD into the extracellular (EC) space, and (3) a class B1 hormone at the free amino(N)-terminal EC end. The recombinant nature of these constructs enables site-directed mutagenesis and generation of virtually unlimited numbers of tethered ligand variants, a feature that can be exploited to rapidly optimize activity as well as interconvert clinically important peptide agonists and antagonists. In this application, we propose to extend the tethered ligand strategy to class A receptors, the largest group of GPCRs (~360 members) which includes the majority of established as well as candidate therapeutic targets. Extension of our technology to class A GPCRs will set the stage to (a) better understand peptide-receptor interactions, (b) expedite the development of peptide therapeutics and (c) produce transgenic animals expressing tissue-specific tethered modulators to dissect the functions of selected GPCRs in vivo. It can be anticipated that the application of membrane-tethered ligands will significantly expand current insight into the biological roles of members of the GPCR superfamily.
Competitiondate
200902
Approvedterm2
2 yrs 6 mths
Pinamesdelim
Fortin, Jean-Philippe
Approvedterm
2 ans 6 mois
Cihrcontribution2
~ $125,000~ $0~